Cargando…
The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatmen...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304692/ https://www.ncbi.nlm.nih.gov/pubmed/35875121 http://dx.doi.org/10.3389/fonc.2022.940263 |
_version_ | 1784752147008585728 |
---|---|
author | Wang, Xinwei Zeng, Yun Zhang, Junling Huang, Mengli Yin, Bijian |
author_facet | Wang, Xinwei Zeng, Yun Zhang, Junling Huang, Mengli Yin, Bijian |
author_sort | Wang, Xinwei |
collection | PubMed |
description | Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future. |
format | Online Article Text |
id | pubmed-9304692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93046922022-07-23 The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review Wang, Xinwei Zeng, Yun Zhang, Junling Huang, Mengli Yin, Bijian Front Oncol Oncology Gastric cancer (GC) is a disease with macromolecular phenotypic heterogeneity and poor prognosis, especially for metastatic GC (mGC). Chemotherapy is the first choice for second-line treatment. However, the benefits of second-line chemotherapy are limited, so there is an urgent need for new treatment regimens to improve patient outcomes. A 65-year-old man with mGC was HER-2 positive. Standard trastuzumab, combined with chemotherapy, was given in the first-line therapy and progression-free survival (PFS) was 8 months. Second-line treatment with pyrotinib in combination with trastuzumab and chemotherapy yielded a PFS of 20 months, in sharp contrast to a median survival of 2.9-6.2 months for a majority of advanced GC patients. This case provides a meaningful reference for the second-line treatment of mGC patients with HER-2 positive. This case also provides valuable information on the response to pyrotinib plus trastuzumab of patients with brain metastases and a better understanding of dual target combination therapy applications in the future. Frontiers Media S.A. 2022-07-08 /pmc/articles/PMC9304692/ /pubmed/35875121 http://dx.doi.org/10.3389/fonc.2022.940263 Text en Copyright © 2022 Wang, Zeng, Zhang, Huang and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wang, Xinwei Zeng, Yun Zhang, Junling Huang, Mengli Yin, Bijian The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
title | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
title_full | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
title_fullStr | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
title_full_unstemmed | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
title_short | The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review |
title_sort | durable effect of pyrotinib plus trastuzumab and chemotherapy in her2-positive gastric cancer with brain metastases: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304692/ https://www.ncbi.nlm.nih.gov/pubmed/35875121 http://dx.doi.org/10.3389/fonc.2022.940263 |
work_keys_str_mv | AT wangxinwei thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT zengyun thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT zhangjunling thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT huangmengli thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT yinbijian thedurableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT wangxinwei durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT zengyun durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT zhangjunling durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT huangmengli durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview AT yinbijian durableeffectofpyrotinibplustrastuzumabandchemotherapyinher2positivegastriccancerwithbrainmetastasesacasereportandliteraturereview |